Fig. 3.

Cascade of care flow-chart.

∗Only participants who were screened up until April 2022 (n = 821) were eligible for being screened again, as the study closed in April 2023 and there had to be ∼1 year between the first and second screening session. SVR12, sustained virologic response 12 weeks after treatment completion.